Business
Bexmarilimab granted key US patent
Bexmarilimab granted key US patent.
About this update from Faron Pharmaceuticals Oy
[{"type":"text","content":"\n \n \n \n RNS Number : 7146B\n Faron Pharmaceuticals Oy\n 14 June 2021\n \n \n \n \n Faron Pharmaceuticals Oy\n \n \n (\"Faron\" or the \"Company\")\n \n \n Bexmarilimab granted key US patent\n \n \n \n \n \n \n Company announcement, 14 June 2021 at 9.00 AM (EEST)\n \n \n \n \n \n \n \n \n \n \n TURKU - FINLAND \n \n - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today announces that the United States Patent and Trademark Office has granted a new US Patent, No. 11,046,761,\n with claims protecting the composition of matter of bexmarilimab. The patent will be issued on 29 June, 2021. \n \n \n \n \n \n Faron's wholly-owned novel precision cancer immunotherapy drug candidate, bexmarilimab, targets the Clever-1 receptor, known to be expressed on immunosuppressive macrophages in the tumour microenvironment and circulating in soluble form, and which is capable of directly inhibiting T-cell activation. The reprogramming of these Clever-1 positive macrophages by bexmarilimab, from an immunosuppressive state to an immune-stimulating one, is believed to be a key immune defence against tumour growth and spread.\n \n \n \n \n \n \n Bexmarilimab\n \n is currently being investigated in the ongoing Phase I/II MATINS trial as a potential monotherapy in patients with solid tumours who have exhausted all treatment options. Latest data from the trial have shown strong initial safety and tolerability, and promising anti-tumour activity in several refractory metastatic solid tumours - cutaneous melanoma, gastric cancer and cholangiocarcinoma.\n \n \n \n \n \n The US composition of matter patent covers bexmarilimab's binding sequences and Clever-1's corresponding epitope - specific elements of the antibody-antigen binding site. The expiry date, not including any potential extensions, is expected to be 2037. \n \n \n \n \n \n The same patent has been granted in Japan and applications are under review in other key territories including Europe and China.\n \n \n \n \n \n \n Dr. Markku Jalkanen, Faron's CEO, said:\n \n \"We are extremely pleased to receive this key patent approval which grants us market exclusivity up to 2037. This patent protection applies specifically to the binding process between bexmarilimab and its target, the Clever-1 recep...